Self-Reported Quit Aids and Assistance Used By Smokers At Their Most Recent Quit Attempt: Findings from the 2020 International Tobacco Control Four Country Smoking and Vaping Survey.


Journal

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751

Informations de publication

Date de publication:
29 08 2021
Historique:
received: 15 12 2020
accepted: 06 04 2021
pubmed: 11 4 2021
medline: 25 11 2021
entrez: 10 4 2021
Statut: ppublish

Résumé

This study retrospectively describes smoking cessation aids, cessation services, and other types of assistance used by current and ex-smokers at their last quit attempt in four high-income countries. Data are from the Wave 3 (2020) International Tobacco Control Four Country Smoking and Vaping Survey in Australia, Canada, England, and the United States (US). Eligible respondents were daily smokers or past-daily recent ex-smokers who made a quit attempt/quit smoking in the last 24-months, resulting in 3614 respondents. Self-reported quit aids/assistance included: nicotine vaping products (NVPs), nicotine replacement therapy (NRT), other pharmacological therapies (OPT: varenicline/bupropion/cytisine), tobacco (noncombustible: heated tobacco product/smokeless tobacco), cessation services (quitline/counseling/doctor), other cessation support (e.g., mobile apps/website/pamphlets, etc.), or no aid. Among all respondents, at last quit attempt, 28.8% used NRT, 28.0% used an NVP, 12.0% used OPT, 7.8% used a cessation service, 1.7% used a tobacco product, 16.5% other cessation support, and 38.6% used no aid/assistance. Slightly more than half of all smokers and ex-smokers (57.2%) reported using any type of pharmacotherapy (NRT or OPT) and/or an NVP, half-used NRT and/or an NVP (49.9%), and 38.4% used any type of pharmacotherapy (NRT and/or OPT). A quarter of smokers/ex-smokers used a combination of aids. NVPs and NRT were the most prevalent types of cessation aids used in all four countries; however, NRT was more commonly used in Australia relative to NVPs, and in England, NVPs were more commonly used than NRT. The use of NVPs or NRT was more evenly distributed in Canada and the US. It appears that many smokers are still trying to quit unassisted, rather than utilizing cessation aids or other forms of assistance. Of those who did use assistance, NRT and NVPs were the most common method, which appears to suggest that nicotine substitution is important for smokers when trying to quit smoking. Clinical practice guidelines in a number of countries state that the most effective smoking cessation method is a combination of pharmacotherapy and face-to-face behavioral support by a health professional. Most quit attempts however are made unassisted, particularly without the use of government-approved cessation medications. This study found that about two in five daily smokers used approved cessation medications (nicotine replacement therapy (NRT) or other approved pharmacotherapies, such as varenicline). Notably, nicotine substitution in the form of either NRT and nicotine vaping products (NVPs) were the most common method of cessation assistance (used by one in two respondents), but the proportion using NRT and/or NVPs varied by country. Few smokers who attempted to quit utilized cessation services such as stop-smoking programs/counseling or quitlines, despite that these types of support are effective in helping smokers manage withdrawals and cravings. Primary healthcare professionals should ask their patients about smoking and offer them evidence-based treatment, as well as be prepared to provide smokers with a referral to trained cessation counselors, particularly when it comes to tailoring intensive treatment programs for regular daily smokers. Additionally, healthcare providers should be prepared to discuss the use of NVPs, particularly if smokers are seeking advice about NVPs, wanting to try/or already using an NVP to quit smoking, have failed repeatedly to quit with other cessation methods, and/or if they do not want to give up tobacco/nicotine use completely.

Identifiants

pubmed: 33837435
pii: 6219622
doi: 10.1093/ntr/ntab068
pmc: PMC8403237
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1699-1707

Subventions

Organisme : NCI NIH HHS
ID : P01 CA200512
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA229974
Pays : United States
Organisme : CIHR
ID : FDN-148477
Pays : Canada

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco.

Auteurs

Shannon Gravely (S)

Department of Psychology, University of Waterloo, Waterloo, Ontario, N2L 3G1, Canada.

K Michael Cummings (KM)

Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.

David Hammond (D)

School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada.

Ron Borland (R)

Melbourne Centre for Behaviour Change, School of Psychological Sciences, University of Melbourne, Melbourne VIC, Australia.

Ann McNeill (A)

Department of Addictions, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Shaping Public Health Policies to Reduce Inequalities & Harm (SPECTRUM), UK.

Katherine A East (KA)

School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada.
Department of Addictions, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Ruth Loewen (R)

Department of Psychology, University of Waterloo, Waterloo, Ontario, N2L 3G1, Canada.

Nadia Martin (N)

Department of Psychology, University of Waterloo, Waterloo, Ontario, N2L 3G1, Canada.

Hua-Hie Yong (HH)

School of Psychology, Deakin University, Geelong, Victoria, 3220, Australia.

Lin Li (L)

Melbourne Centre for Behaviour Change, School of Psychological Sciences, University of Melbourne, Melbourne VIC, Australia.

Alex Liber (A)

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, NW, Washington, DC, USA.

David T Levy (DT)

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, NW, Washington, DC, USA.

Anne C K Quah (ACK)

Department of Psychology, University of Waterloo, Waterloo, Ontario, N2L 3G1, Canada.

Janine Ouimet (J)

Department of Psychology, University of Waterloo, Waterloo, Ontario, N2L 3G1, Canada.

Sara C Hitchman (SC)

Department of Addictions, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Mary E Thompson (ME)

Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada.

Christian Boudreau (C)

Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada.

Geoffrey T Fong (GT)

Department of Psychology, University of Waterloo, Waterloo, Ontario, N2L 3G1, Canada.
Ontario Institute for Cancer Research, Toronto, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH